Clear cell adenocarcinoma of the urethra: review of the literature

Int J Surg Oncol. 2015:2015:790235. doi: 10.1155/2015/790235. Epub 2015 Jan 20.

Abstract

Background: Clear cell adenocarcinoma of the urethra (CCAU) is extremely rare and a number of clinicians may be unfamiliar with its diagnosis and biological behaviour.

Aims: To review the literature on CCAU.

Methods: Various internet databases were used.

Results/literature review: (i) CCAU occurs in adults and in women in the great majority of cases. (ii) It has a particular association with urethral diverticulum, which has been present in 56% of the patients; is indistinguishable from clear cell adenocarcinoma of the female genital tract but is not associated with endometriosis; and probably does not arise by malignant transformation of nephrogenic adenoma. (iii) It is usually, readily distinguished from nephrogenic adenoma because of greater cytological a-typicality and mitotic activity and does not stain for prostate-specific antigen or prostatic acid phosphatase. (iv) It has been treated by anterior exenteration in women and cystoprostatectomy in men and at times by radiotherapy; chemotherapy has rarely been given. (v) CCAU is aggressive with low 5-year survival rates. (vi) There is no consensus opinion of treatment options that would improve the prognosis.

Conclusions: Few cases of CCAU have been reported. Urologists, gynaecologists, pathologists, and oncologists should report cases of CCAU they encounter and enter them into a multicentric trial to determine the best treatment options that would improve the prognosis.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma, Clear Cell* / diagnosis
  • Adenocarcinoma, Clear Cell* / mortality
  • Adenocarcinoma, Clear Cell* / therapy
  • Combined Modality Therapy
  • Diagnosis, Differential
  • Humans
  • Prognosis
  • Treatment Outcome
  • Urethral Neoplasms* / diagnosis
  • Urethral Neoplasms* / mortality
  • Urethral Neoplasms* / therapy